Recombinant Human TWEAK Receptor
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Description | TWEAKR belongs to the TNF family of transmembrane proteins and contains a cytoplasmic "death domain", which can activated the cell's apoptotic machinery. It is expressed in the spleen, thymus, peripheral blood lymphocytes, colon, and small intestine. Signal transduction by TWEAKR can be activated by either the membrane anchored or the soluble TWEAK. Recombinant soluble TWEAKR is a 53 amino acid polypeptide (5.6 kDa) comprising the entire extracellular domain of the full length TWEAKR protein. |
---|---|
BiologicalActivity | Determined by its ability to inhibit TWEAK-induced weak cell death of HT29 cells. The expected ED50 for this effect is 1.0-3.0 µg/ml. |
Authenticity | Verified by N-terminal and Mass Spectrometry analyses (when applicable). |
Endotoxin | Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg). |
Protein Content | Verified by UV Spectroscopy and/or SDS-PAGE gel. |
Storage | -20°C |
Precautions | Recombinant Human TWEAK Receptor is for research use only and not for use in diagnostic or therapeutic procedures. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.